The JAMA article also noted VA nationwide system of hospitals and specialized centers of excellence make the Department ‘s unique ability to organize such large, multi-site testing of new therapies and medical devices VA patient population. For for studies of treatments for chronic diseases in the elderly.

The work was supported by two postdocs, Alison Skelley, who worked in Voldman laboratory, and Oktay Kirak who works cited with Jaenisch. Skelley and Kirak are lead authors of the Nature Methods paper. Heikyung Suh, a technical officer in the Whitehead Institute, is also author of the paper.


In addition, said Sudore, limited alphabetization would result ill controlled chronic medical condition for have the course of time – that, their disease burden high as you it disturbs with cognitive, being ‘s processing .

KineMed pioneer work having a direct, informational way to explore the extent and speed the progress of the fibrosis, which assess synthesis of collagen in the vivo in humans and animals measures. This Company believes that his own way to which many challenges of when presenting of new drugs, company is working patient be deal having fibrotic disorders of for which no effective treatments gives confronted. Marc Hellerstein, KineMed academic the founder and a professor at UCSF and uc berkely, said: ‘We hope will KineMed A romantic technique the vast number of drugs to the large number of patients with diseases to handle in which fibrosis of playing a central role. This unexpected anti – fibrotic activity observed with animals to Noscapine encouraged us consider making forward of clinical trials better evaluate its potential. We are interest that our results will potential potential pharmaceutical partners are satisfactory. ‘.

Other articles from category "prevention":

Random articles